FUB-PB-22

(Redirected from QUFUBIC)

FUB-PB-22 (QUFUBIC) is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1][2]

FUB-PB-22
Legal status
Legal status
Identifiers
  • quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H17FN2O2
Molar mass396.421 g·mol−1
3D model (JSmol)
  • Fc1ccc(cc1)Cn1cc(c2c1cccc2)C(=O)Oc1cccc2c1nccc2
  • InChI=1S/C25H17FN2O2/c26-19-12-10-17(11-13-19)15-28-16-21(20-7-1-2-8-22(20)28)25(29)30-23-9-3-5-18-6-4-14-27-24(18)23/h1-14,16H,15H2
  • Key:ROHVURVXAOMRJY-UHFFFAOYSA-N

Pharmacology

edit

FUB-PB-22 acts as a full agonist with a binding affinity of 0.386nM at CB1 and 0.478nM at CB2 cannabinoid receptors.[3]

edit

FUB-PB-22 is an Anlage II controlled substance in Germany. It was scheduled in Japan in July 2014.

As of October 2015 FUB-PB-22 is a controlled substance in China.[4]

It is also banned in Sweden.[5]

See also

edit

References

edit
  1. ^ "FUB-PB-22". Southern Association of Forensic Scientists. Archived from the original on 27 May 2015. Retrieved 23 July 2015.
  2. ^ Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T (February 2015). "N-OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products". Forensic Toxicology. 33 (2): 244–259. doi:10.1007/s11419-015-0268-7. PMC 4525202. PMID 26257833.
  3. ^ Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (1 July 2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
  4. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
  5. ^ "Cannabinoider föreslås bli klassificerade som hälsofarlig vara". Folkhälsomyndigheten. 28 May 2014. Retrieved 23 July 2015.